search
Back to results

Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients

Primary Purpose

Adrenal Insufficiency, Adrenal Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Cosyntropin stimulation test
Sponsored by
Bnai Zion Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Adrenal Insufficiency focused on measuring cosyntropin, salivary free cortisol, mitotane

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • mitotane treated
  • known hypoadrenlism

Exclusion Criteria:

  • pregnancy

Sites / Locations

  • Bnai Zion MCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

healthy subjects

hypoadrenal mitotane treated patients

hypoadrenal no-mitotane treated patients

Arm Description

low-dose cosyntropin stimulation test

low-dose cosyntropin stimulation test

low-dose cosyntropin stimulation test

Outcomes

Primary Outcome Measures

Salivary free cortisol
Salivary free cortisol concentrations during intravenous low dose cosyntropin stimulation test..

Secondary Outcome Measures

serum cortisol
Serum cortisol concentrations during intravenous low dose cosyntropin stimulation test.

Full Information

First Posted
March 14, 2017
Last Updated
January 17, 2019
Sponsor
Bnai Zion Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03083834
Brief Title
Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients
Official Title
Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 14, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
December 31, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bnai Zion Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since mitotane increases cortisol binding globulin levels (CBG), artificially raising total cortisol. Salivary free cortisol (SC) is not affected by CBG alterations, and reflects the free serum cortisol. In the current study, investigators will assess serum and SC responses during low-dose cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on steroid replacement therapy and in patients who suffer from hypoadrenlism caused from other etiology. Investigators will compare results between groups and try to demonstrate the superiority of SC in assessing adrenal function in mitotane treated patients.
Detailed Description
80-90% of circulating cortisol is bound to cortisol binding globulin (CBG) or transcortin, whereas only 3-10% is in the free state. Salivary free cortisol (SC) is an index of plasma free cortisol. In previous studies it was shown that in low-dose cosyntropin stimulation test, SC increases significantly in normal but not in hypoadrenal patients. It was suggested that dynamic assessment of the SC response to ACTH may be particularly helpful whenever the measurement of serum cortisol is complicated by increased or decreased CBG levels. Adrenocortical carcinoma (ACC) is a rare malignancy with a heterogeneous presentation and a variable but generally poor prognosis. Mitotane is the main drug for ACC treatment and it plays a role both in adjuvant treatment after complete resection and in recurrent, inoperable and/or metastatic ACC. Mitotane blocks adrenocortical steroid synthesis and also exerts a specific cytotoxic effect on adrenocortical cells. Mitotane induces adrenal insufficiency, requiring hydrocortisone replacement therapy. In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since mitotane increases CBG levels, artificially raising total cortisol. SC is not affected by CBG alterations, and reflects the free serum cortisol and may be more accurate in diagnosing hypoadrenalism in mitotane treated patients. In the current study, investigators will assess serum and SC responses during low-dose cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on steroid replacement therapy and in patients who suffer from hypoadrenlism caused from any other etiology. Investigators will compare results between groups and try to demonstrate the superiority of SC in assessing adrenal function in mitotane treated patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adrenal Insufficiency, Adrenal Cancer
Keywords
cosyntropin, salivary free cortisol, mitotane

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
healthy subjects
Arm Type
Experimental
Arm Description
low-dose cosyntropin stimulation test
Arm Title
hypoadrenal mitotane treated patients
Arm Type
Experimental
Arm Description
low-dose cosyntropin stimulation test
Arm Title
hypoadrenal no-mitotane treated patients
Arm Type
Experimental
Arm Description
low-dose cosyntropin stimulation test
Intervention Type
Diagnostic Test
Intervention Name(s)
Cosyntropin stimulation test
Intervention Description
At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
Primary Outcome Measure Information:
Title
Salivary free cortisol
Description
Salivary free cortisol concentrations during intravenous low dose cosyntropin stimulation test..
Time Frame
1 day
Secondary Outcome Measure Information:
Title
serum cortisol
Description
Serum cortisol concentrations during intravenous low dose cosyntropin stimulation test.
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: mitotane treated known hypoadrenlism Exclusion Criteria: pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Leonard Saiegh, MD
Phone
+972506267262
Email
leonard.saiegh@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonard Saiegh, MD
Organizational Affiliation
Bnai Zion Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bnai Zion MC
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonard Saiegh
Phone
506267262
Email
leonard.saiegh@gmail.com
First Name & Middle Initial & Last Name & Degree
Michal Yeiches
Phone
0528283062
Email
yeiches@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients

We'll reach out to this number within 24 hrs